Register Login

All Posts

Review: Non-antithrombotic Strategies for Venous Thromboembolism Prophylaxis

Check with your medical library for this provocative review of VTE prevention: Gurumurthy G, Thachil J. Nonanticoagulant strategies for venous thromboembolism prophylaxis. Semin Thromb Hemost. 2026;52:236–47. doi: 10.1055/a-2712-3534. PMID: 41092960. Abstract Venous thromboembolism (VTE) remains a major cause of preventable morbidity and mortality. Prophylaxis with anticoagulation is limited by bleeding risk, contraindications, and patient-specific factors. […]
read more

Letter to 2024 NEJM Links Adenoviral Anti-PF4 to VITT

Click here for the full news release from Flinders University News: New research, led by Flinders University and international experts, has finally uncovered how a rare blood-clotting condition can occur after some COVID-19 adenovirus-based vaccines or after a natural adenovirus infection. First paragraph: To the Editor: Disorders caused by antibodies against platelet factor 4 (PF4) gained […]
read more

Enhanced Coagulation Potential FVIII

See this open-access article that describes a synthetic enhanced coagulation potential FVIII. This preparation reflects the enhanced activity FIX Padua. Kashiwakura Y, Nakajima Y, Horinaka K, et al. Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy. Blood. 2026;147:402–15. doi: 10.1182/blood.2025028481. PMID: 41198051. Abstract Click here for the visual […]
read more

Normalized Activated Protein C Sensitivity Ratio Predicts VTE in OCR

Here is an open-access report on a noteworthy primary research piece detailing an assay that predicts VTE risk associated with oral contraceptives: Morimont L, Creinin MD, Gaspard U, Foidart JM, and Douxfils J. Predicting venous thromboembolism risk from an endogenous thrombin potential-based normalized activated protein C sensitivity ratio assay: toward early assessment of combined oral […]
read more